疫苗佐剂市场 - 全球产业规模、份额、趋势、机会和预测，按产品、类型、应用、地区和竞争细分，2020-2030 年

2024 年全球疫苗佐剂市场价值为 7.2 亿美元，预计在预测期内将实现强劲增长，到 2030 年的复合年增长率为 6.56%。全球疫苗佐剂市场是更广泛的医疗保健产业的重要组成部分，在提高疫苗效力和加强全球免疫工作方面发挥关键作用。疫苗佐剂是一种添加到疫苗中的物质，以刺激更强、更持久的免疫反应，最终提高对传染病的保护作用。近年来，由于对抗病毒感染、细菌性疾病和新出现的流行病等多种疾病的疫苗需求不断增长，该市场出现了显着增长。

主要市场驱动因素

传染病威胁不断上升

主要市场挑战

监管障碍

主要市场趋势

扩大消费市场

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第四章：全球疫苗佐剂市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 副产品（佐剂乳液、病原体成分、皂苷佐剂、颗粒佐剂、其他佐剂）
  • 依类型（人用疫苗佐剂、兽用疫苗佐剂）
  • 按应用（研究应用、商业应用）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按产品
  • 按类型
  • 按应用
  • 按地区

第 5 章：亚太地区疫苗佐剂市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品
  • 按类型
  • 按应用
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第六章：欧洲疫苗佐剂市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美疫苗佐剂市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲疫苗佐剂市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 9 章：中东和非洲疫苗佐剂市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及

第 10 章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 12 章：全球疫苗佐剂市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Dynavax Technologies
• Croda International Plc
• Gsk Plc
• Novavax
• Spi Pharma (A Subsidiary of Associated British Foods Plc)
• Agenus Inc.
• Phibro Animal Health Corporation
• Aurorium (Formerly Vertellus)
• Merck Kgaa
• Vaxine Pty Ltd.

第 15 章：策略建议

第16章调查会社について・免责事项

Global Vaccine Adjuvants Market was valued at USD 0.72 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.56% through 2030. The Global Vaccine Adjuvants Market is a critical component of the broader healthcare industry, playing a pivotal role in enhancing the efficacy of vaccines and bolstering global immunization efforts. Vaccine adjuvants are substances added to vaccines to stimulate a stronger and longer-lasting immune response, ultimately leading to improved protection against infectious diseases. This market has witnessed significant growth in recent years, driven by the increasing demand for vaccines to combat a wide range of diseases, including viral infections, bacterial illnesses, and emerging pandemics.

Key Market Drivers

Rising Infectious Disease Threats

The Global Vaccine Adjuvants Market is experiencing a notable upswing, and one of the primary driving forces behind this growth is the persistent and escalating threat posed by infectious diseases. In recent years, the world has witnessed a series of infectious disease outbreaks and pandemics that have underscored the critical importance of vaccination and vaccine adjuvants in safeguarding public health. These threats have led to a surge in demand for adjuvants, which play a pivotal role in enhancing the efficacy of vaccines and ensuring rapid and robust immune responses. For instance, according to the World Health Organization, infectious diseases are responsible for over 17 million deaths annually. Over the past two decades, 30 new infectious diseases have emerged, posing significant global health challenges and highlighting the urgent need for innovative prevention, treatment, and surveillance strategies.

Key Market Challenges

Regulatory Hurdles

One of the most formidable challenges for vaccine adjuvants is the arduous journey through the regulatory approval process. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require extensive preclinical and clinical data to demonstrate the safety and efficacy of new adjuvants. These rigorous requirements can significantly lengthen the timeline from development to market approval, delaying adjuvant availability and increasing development costs.

Regulatory requirements for vaccine adjuvants vary from one country or region to another. This lack of harmonization can create a complex and fragmented landscape for manufacturers seeking global approval. Adhering to multiple sets of regulations necessitates additional resources and can discourage investment in adjuvant research and development. Regulatory agencies often provide limited guidance or specific pathways for the approval of adjuvants. Manufacturers are left to navigate the regulatory process with minimal clear direction, which can result in uncertainty and potential missteps during development and submission. Clarity and consistent guidelines would be instrumental in streamlining the approval process.

Key Market Trends

Expanding Consumer Markets

The Global Vaccine Adjuvants Market is experiencing a significant boost, thanks to the expansion of consumer markets across the globe. As public awareness about the importance of vaccines continues to grow, the demand for effective immunization has surged, propelling the need for vaccine adjuvants. Several factors contribute to the expansion of consumer markets and their positive impact on the vaccine adjuvants market. Rising global populations, particularly in emerging economies, are driving an increased demand for vaccines. As more people seek protection against infectious diseases, vaccine manufacturers are ramping up their production. Vaccine adjuvants play a pivotal role in enhancing the efficacy of vaccines, making them more attractive to a broader consumer base.

Furthermore, the prevalence of infectious diseases remains a global concern. Outbreaks and pandemics like the COVID-19 crisis have highlighted the critical need for vaccines to prevent and control the spread of diseases. This heightened awareness of infectious disease threats has motivated individuals and governments to invest in vaccination programs, further fueling the demand for adjuvanted vaccines.

Key Market Players

• Dynavax Technologies
• Croda International Plc
• Gsk Plc
• Novavax
• Spi Pharma (A Subsidiary of Associated British Foods Plc)
• Agenus Inc.
• Phibro Animal Health Corporation
• Aurorium (Formerly Vertellus)
• Merck Kgaa
• Vaxine Pty Ltd

Report Scope:

In this report, the Global Vaccine Adjuvants Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vaccine Adjuvants Market, By Product:

• Adjuvant Emulsions
• Pathogen Components
• Saponin-Based Adjuvants
• Particulate Adjuvants
• Other Adjuvants

Vaccine Adjuvants Market, By Type:

• Human Vaccine Adjuvants
• Veterinary Vaccine Adjuvants

Vaccine Adjuvants Market, By Application:

• Research Applications
• Commercial Applications

Vaccine Adjuvants Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vaccine Adjuvants Market.

Available Customizations:

Global Vaccine Adjuvants Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Vaccine Adjuvants Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Product (Adjuvant Emulsions, Pathogen Components, Saponin-Based Adjuvants, Particulate Adjuvants, Other Adjuvants)
  • 4.2.2. By Type (Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants)
  • 4.2.3. By Application (Research Applications, Commercial Applications)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Product
  • 4.3.2. By Type
  • 4.3.3. By Application
  • 4.3.4. By Region

5. Asia Pacific Vaccine Adjuvants Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product
  • 5.2.2. By Type
  • 5.2.3. By Application
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Vaccine Adjuvants Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Product
      • 5.3.1.2.2. By Type
      • 5.3.1.2.3. By Application
  • 5.3.2. India Vaccine Adjuvants Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Product
      • 5.3.2.2.2. By Type
      • 5.3.2.2.3. By Application
  • 5.3.3. Australia Vaccine Adjuvants Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Product
      • 5.3.3.2.2. By Type
      • 5.3.3.2.3. By Application
  • 5.3.4. Japan Vaccine Adjuvants Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Product
      • 5.3.4.2.2. By Type
      • 5.3.4.2.3. By Application
  • 5.3.5. South Korea Vaccine Adjuvants Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Product
      • 5.3.5.2.2. By Type
      • 5.3.5.2.3. By Application

6. Europe Vaccine Adjuvants Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Type
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Vaccine Adjuvants Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Application
  • 6.3.2. Germany Vaccine Adjuvants Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Application
  • 6.3.3. Spain Vaccine Adjuvants Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Application
  • 6.3.4. Italy Vaccine Adjuvants Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Type
      • 6.3.4.2.3. By Application
  • 6.3.5. United Kingdom Vaccine Adjuvants Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Type
      • 6.3.5.2.3. By Application

7. North America Vaccine Adjuvants Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Type
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Vaccine Adjuvants Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Application
  • 7.3.2. Mexico Vaccine Adjuvants Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Application
  • 7.3.3. Canada Vaccine Adjuvants Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Application

8. South America Vaccine Adjuvants Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Type
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Vaccine Adjuvants Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Application
  • 8.3.2. Argentina Vaccine Adjuvants Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Application
  • 8.3.3. Colombia Vaccine Adjuvants Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Application

9. Middle East and Africa Vaccine Adjuvants Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Type
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Vaccine Adjuvants Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Application
  • 9.3.2. Saudi Arabia Vaccine Adjuvants Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Application
  • 9.3.3. UAE Vaccine Adjuvants Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Application
  • 9.3.4. Egypt Vaccine Adjuvants Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product
      • 9.3.4.2.2. By Type
      • 9.3.4.2.3. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Vaccine Adjuvants Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Dynavax Technologies
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Croda International Plc
• 14.3. Gsk Plc
• 14.4. Novavax
• 14.5. Spi Pharma (A Subsidiary of Associated British Foods Plc)
• 14.6. Agenus Inc.
• 14.7. Phibro Animal Health Corporation
• 14.8. Aurorium (Formerly Vertellus)
• 14.9. Merck Kgaa
• 14.10. Vaxine Pty Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer